ZA200409137B - Combinations comprising epothilones and pharmaceutical uses thereof - Google Patents

Combinations comprising epothilones and pharmaceutical uses thereof Download PDF

Info

Publication number
ZA200409137B
ZA200409137B ZA2004/09137A ZA200409137A ZA200409137B ZA 200409137 B ZA200409137 B ZA 200409137B ZA 2004/09137 A ZA2004/09137 A ZA 2004/09137A ZA 200409137 A ZA200409137 A ZA 200409137A ZA 200409137 B ZA200409137 B ZA 200409137B
Authority
ZA
South Africa
Prior art keywords
inhibitors
combination
topoisomerase
hydrogen
lower alkyl
Prior art date
Application number
ZA2004/09137A
Other languages
English (en)
Inventor
David Rothermel John
Wartmann Markus
Arthur Hohneker John
Ann Miller Julie
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200409137B publication Critical patent/ZA200409137B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA2004/09137A 2002-06-10 2004-11-11 Combinations comprising epothilones and pharmaceutical uses thereof ZA200409137B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US38702502P 2002-06-10 2002-06-10
US40623902P 2002-08-27 2002-08-27
US40623802P 2002-08-27 2002-08-27
US43867603P 2003-01-08 2003-01-08
US43867703P 2003-01-08 2003-01-08
PCT/EP2003/005988 WO2003103712A1 (en) 2002-06-01 2003-06-06 Combinations comprising epothilones and pharmaceutical uses thereof

Publications (1)

Publication Number Publication Date
ZA200409137B true ZA200409137B (en) 2005-08-31

Family

ID=29741146

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2004/09137A ZA200409137B (en) 2002-06-10 2004-11-11 Combinations comprising epothilones and pharmaceutical uses thereof

Country Status (16)

Country Link
US (2) US20050271669A1 (https=)
EP (2) EP2179745A1 (https=)
JP (1) JP2005535608A (https=)
CN (2) CN1658904A (https=)
AT (1) ATE476995T1 (https=)
AU (1) AU2003242646A1 (https=)
BR (1) BR0311714A (https=)
CA (1) CA2487147A1 (https=)
DE (1) DE60333754D1 (https=)
IL (1) IL165180A0 (https=)
MX (1) MXPA04012444A (https=)
NO (1) NO20050096L (https=)
PL (1) PL372070A1 (https=)
SG (1) SG162616A1 (https=)
WO (1) WO2003103712A1 (https=)
ZA (1) ZA200409137B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2518318A1 (en) 2003-03-17 2004-09-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
US7642253B2 (en) 2005-05-11 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
EA200800321A1 (ru) 2005-07-14 2008-06-30 Такеда Сан Диего, Инк. Ингибиторы гистондеацетилазы
WO2008058287A1 (en) * 2006-11-10 2008-05-15 Syndax Pharmaceuticals, Inc. COMBINATION OF ERα+ LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER
US20100298270A1 (en) * 2007-07-23 2010-11-25 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20100267779A1 (en) * 2007-07-23 2010-10-21 Syndax Pharmaceuticals, Inc. Novel Compounds and Methods of Using Them
US20090149511A1 (en) * 2007-10-30 2009-06-11 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC and an mTOR Inhibitor
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
US20110182888A1 (en) * 2008-04-08 2011-07-28 Peter Ordentlich Administration of an Inhibitor of HDAC, an Inhibitor of HER-2, and a Selective Estrogen Receptor Modulator
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
US11998546B2 (en) 2016-10-28 2024-06-04 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and epothilone and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
SK287775B6 (sk) * 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
DE69927790T2 (de) * 1998-02-25 2006-07-20 Sloan-Kettering Institute For Cancer Research Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
WO2000000485A1 (de) * 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
IL144370A0 (en) * 1999-02-11 2002-05-23 Schering Ag Epothilon derivatives, method for the production and the use thereof as pharmaceuticals
DE19908760A1 (de) * 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
CA2401800A1 (en) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE10020899A1 (de) * 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
PE20020354A1 (es) * 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
WO2002072085A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases

Also Published As

Publication number Publication date
US20050271669A1 (en) 2005-12-08
SG162616A1 (en) 2010-07-29
WO2003103712A1 (en) 2003-12-18
NO20050096L (no) 2005-02-04
EP2179745A1 (en) 2010-04-28
MXPA04012444A (es) 2005-04-19
CA2487147A1 (en) 2003-12-18
ATE476995T1 (de) 2010-08-15
US20110033458A1 (en) 2011-02-10
DE60333754D1 (de) 2010-09-23
JP2005535608A (ja) 2005-11-24
HK1075208A1 (en) 2005-12-09
BR0311714A (pt) 2005-03-01
CN101816792A (zh) 2010-09-01
CN1658904A (zh) 2005-08-24
EP1515750B1 (en) 2010-08-11
EP1515750A1 (en) 2005-03-23
PL372070A1 (en) 2005-07-11
AU2003242646A1 (en) 2003-12-22
IL165180A0 (en) 2005-12-18

Similar Documents

Publication Publication Date Title
US20110033458A1 (en) Combinations comprising epothilones and pharmaceutical uses thereof
JP2023533447A (ja) がんを処置する併用療法
US20040034026A1 (en) Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
US20050244407A1 (en) Therapeutic synergy of anti-cancer compounds
US20060205810A1 (en) Platinum therapeutic combinations
JP7717065B2 (ja) Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法
US20040132754A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
JP2008521826A (ja) エポチロンおよびタンパク質チロシンキナーゼ阻害剤を含む組合せ剤およびその医薬的使用
AU2002308218A1 (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
US20050033034A1 (en) Anti-t cell immunotoxin fusion protein and its therapeutic use
NZ550174A (en) Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
AU2008200068B2 (en) Combinations comprising epothilones and pharmaceutical uses thereof
EP1485090B1 (en) Combinations comprising an epothilone derivative and an imidazotetrazinone
RU2379032C2 (ru) Комбинации, включающие эпотилоны, и их фармацевтическое применение
NZ537040A (en) Treating a proliferative disease comprising administering to the animal a combination that comprises (a) a HER-1 or a HER-2 antibody or (b) at least one antineoplastic agent
HK1141234A (en) Combinations comprising epothilones and pharmaceutical uses thereof
CA2573949A1 (en) Epothilone combinations
KR20050019125A (ko) 에포틸론을 포함하는 조합물 및 그의 제약적 용도
HK1075208B (en) Combinations comprising epothilones and pharmaceutical uses thereof
HK1072723B (en) Combinations comprising an epothilone derivatives and an imidazotetrazinone
ZA200306404B (en) Combination comprising a signal transduction inhibitor and an epothilone derivative.